Richter CEO puts 2011 revenue growth at 0-5%

Pharma

Erik Bogsch, CEO of drugmaker Richter Gedeon, said full-year revenue growth in euro-terms would reach 0-5% in 2011, speaking at a press conference after the company published its Q2 report.

Richter sees its sales in Russia rising 10-15% for the full year, up from 5-10% expected earlier, Bogsch said. Russian sales accounted for 30% of revenue in H1, up from 25% in the same period a year earlier, he added.

Russian sales rose 28% in euro terms in H1.

Richter continues to expect sales in Hungary to stagnate, Bogsch said.

Sales and marketing costs are expected to reach 25-27% of revenue this year. The proportion of revenue spent on research and development is expected to be 12-13%.

Richter's report shows higher sales and marketing costs were a big factor behind the drop in Q2 and H1 sales.

Gross margin is expected to reach 60% of revenue this year, edging down from 61.1% in 2010, Bogsch said. Operating margin is likely to fall to 15-16% from 22.8%, he added.

Changes to drug price regulations and subsidies will reduce Richter's full-year profit by HUF 7.1 billion in 2011, he said. An increase in the drug sector tax from July 1 and the drug sales representative fee will account for HUF 4.1 billion of the reduction, he added.

Richter cannot cut prices any further because of these factors, he said.

Richter said in its report that price cuts it made to remain competitive as well as to keep some drugs subsidized would have an impact of about HUF 1 billion for the full year.

In Hungary, Richter has annual profit of about HUF 4.8 billion on sales of HUF 30 billion, Bogsch said.

Compensation for R&D spending next year is uncertain, he said.

Recently approved legislation reduced the proportion of R&D spending companies may deduct from 100% to 50% for 2011.

ADVERTISEMENT

Business confidence improves as consumer sentiment worsens Analysis

Business confidence improves as consumer sentiment worsens

Meeting called to address Pegasus spyware lacks quorum  Parliament

Meeting called to address Pegasus spyware lacks quorum 

Skanska commercial dev unit names new EVP of operations Hung... Appointments

Skanska commercial dev unit names new EVP of operations Hung...

Zsa Zsa Gabor's ashes buried in Budapest City

Zsa Zsa Gabor's ashes buried in Budapest

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.